GANX Stock Forecast: Gain Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Gain Therapeutics, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 32 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Gain Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (79): Analysts have, on balance, been raising their forecasts.
Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
GANX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GANX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 31 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 11 Aug 2026 | BTIG | Reiterates | Buy | $5.00 |
| 1 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 30 June 2026 | BTIG | Maintains | Buy | $5.00 |
| 19 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Oct 2025 | BTIG | Reiterates | Buy | — |
| 13 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Oct 2025 | Maxim Group | Maintains | Buy | — |
| 8 Sept 2025 | BTIG | Reiterates | Buy | — |
| 13 Aug 2025 | Roth Capital | Maintains | Buy | — |
| 3 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | Scotiabank | Initiates | Sector Outperform | — |
| 24 Dec 2024 | Roth MKM | Maintains | Buy | — |
| 5 Dec 2024 | Roth MKM | Initiates | Buy | — |
| 25 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GANX.
This page is one stock. Monday covers all of them.
GANX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
GANX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Gain Therapeutics, Inc. returned −64.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
GANX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 4.4×
- EV / EBITDA
- —
Cheaper than 21% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −223.9%
- Return on assets
- −91.5%
- Dividend yield
- —
Higher than 7% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Gain Therapeutics, Inc. has a market value of $44.5M and an enterprise value of $33.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$20.1M.
Free cash flow in the twelve months to 30 June 2026: −$19.0M.
Gain Therapeutics, Inc. employs 20 people.
Data provided by Twelve Data
GANX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at GANX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Gain Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about GANX
What is the GANX stock price forecast for 2026-2027?
The median 12-month analyst price target for Gain Therapeutics, Inc. is $7, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GANX stock a buy right now?
Of the 5 analysts covering Gain Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Gain Therapeutics, Inc. 32 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GANX?
As at 21 Nov 2026, Gain Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (79 of 100).
Will GANX stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $7, and Ticker Nerd's factor model ranks Gain Therapeutics, Inc. 32 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GANX stock forecast for 2030?
No analyst covering Gain Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GANX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.
How has GANX stock performed over the past year?
Gain Therapeutics, Inc. returned -64.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Gain Therapeutics, Inc. do?
Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for difficult-to-treat diseases. Its current research centers on neurodegenerative disorders and other conditions linked to protein misfolding, with a particular emphasis on Parkinson’s disease and select rare genetic diseases.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for difficult-to-treat diseases. Its current research centers on neurodegenerative disorders and other conditions linked to protein misfolding, with a particular emphasis on Parkinson’s disease and select rare genetic diseases. The company’s lead candidate, GT-02287, is being evaluated for Parkinson’s disease and is part of a broader pipeline aimed at addressing underlying disease mechanisms rather than only managing symptoms. Gain Therapeutics also uses its Magellan drug discovery platform to identify novel allosteric binding sites and design proprietary compounds with the potential to modulate protein function. Headquartered in Bethesda, Maryland, Gain Therapeutics operates as a specialized player in precision medicine and computational drug discovery within the biotechnology sector.
CEO Mr. Gene Mack M.B.A. · 20 employees · United States · https://gaintherapeutics.com